The treatment of retinopathy of prematurity with Avasti
Not Applicable
- Conditions
- Retinopathy of prematurity.Retinopathy of prematurity
- Registration Number
- IRCT2014101618966N2
- Lead Sponsor
- o sponsor
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
all the premature new borns that received intravitreal bevacizumab injections for retinopathy of prematurity
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Regression of retinopathy of prematurity. Timepoint: one week after the intravitreal injection of bevacizumab. Method of measurement: indirect ophthalmoscopy.
- Secondary Outcome Measures
Name Time Method Condition of the retina. Timepoint: 52 weeks after the intravitreal injection of bevacizumab weeks. Method of measurement: indirect ophthalmocsopy.